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relapsing course. Since the incidence and prevalence of CD 
and UC show a continuously increasing trend in Korea and 
other Asian countries, medical scientists have grown more 
interested in these diseases.1-3 With the increasing preva-
lence in IBD and advances in the field of molecular biology, 
an increasing number of studies have investigated IBD, and 
this trend is not just limited to IBD. Expanded infrastructure 
and clinical research capabilities have contributed to the ad-
vancement of clinical studies investigating various kinds of 
disease during the last two decades.4 After the second world 
war, medical ethics expanded to ethical principles for clinical 
research, based on the Nuremberg Code published in 1947 
and the Declaration of Helsinki published in 1964, and the 
necessity of Institutional Review Board (IRB) approval was 
first introduced.5 All research using human subjects, such as 
clinical trials for new drug/medical device approval, in addi-
INTRODUCTION
Inflammatory bowel disease (IBD), which mainly con-
sists of UC, CD, and intestinal Behçet’s disease, involves 
chronic inflammation of the gastrointestinal (GI) tract with 
unknown etiology, and is characterized by a remitting and 
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tion to human biospecimen research, must be reviewed and 
approved by an IRB. The IRB process serves an important 
and basic role in the protection of clinical research and hu-
man research subjects. However, IRB review and approval 
can sometimes be burdensome for investigators. Thus, in-
vestigators are committed to conducting high quality clinical 
research by designing a clinical study protocol in a time effi-
cient-manner and in accordance with laws and regulations, 
and to going through the IRB review process. Investigators 
studying rare diseases have difficulty gaining approval from 
IRBs or other government agencies (Food and Drug Admin-
istration etc.), and this seems to be attributed to the lack of 
information and knowledge on these diseases. Close coop-
eration between experts with experience in rare disorders 
and investigators can help in successfully navigating the IRB 
approval process.6 
IBD is considered a rare and intractable disorder in Korea. 
Since IBD is a chronic disorder, unlike common GI diseases, 
some considerations need to be taken into account when 
gaining IRB approval according to reviewers’ or sponsors’ 
experience, study protocol, and IRB submission and review. 
A few studies have been performed on the IRB process so 
far.7 In the 1970s, previous studies mainly investigated the 
structure of IRB, workforce, work intensity, and the scope of 
studies subject to review.8-11 IRB review has been found to fo-
cus on obtaining written informed consent and agreement.12 
Subsequently, studies on deviations from IRB review results 
by institutions were carried out in relation to reviews for 
multi-institutional clinical trials, and differences in evalua-
tion outcomes and IRB comments, even with the same study 
design, were statistically significant.13-15 However, no studies 
have suggested guidelines for study protocols or for investi-
gators receiving reviews through analysis of IRB evaluation 
outcomes and comments, or have been performed on the 
characteristics of the IRB’s review of research on rare dis-
eases such as IBD in Korea. 
Therefore, this study aims to identify differences between 
IBD and non-IBD GI studies by analyzing factors such as re-
view types, evaluation outcomes, approval processing times, 
and comments. 
METHODS
1. Materials and Methods
This study involved 381 GI disease research proposals 
reviewed by the IRB of Severance Hospital, Yonsei Univer-
sity Health System, between January 1, 2009 and December 
31, 2013. To collect accurate data, we included studies per-
formed by principal investigators in the Division of Gastro-
enterology, and excluded studies performed by investigators 
from other departments such as General Surgery or Oncol-
ogy. Studies on CD, UC, and intestinal Behçet’s disease, and 
studies simultaneously investigating IBD and other GI dis-
eases were classified into the IBD group. 
We examined types of clinical studies (investigator-initiat-
ed trials [IITs]), sponsor-initiated trials [SITs]), study phases, 
results of initial reviews, and durations from submission to 
approval based on the IRB database managed by the Human 
Research Protection Center, Severance Hospital, Korea. We 
also analyzed research risk levels determined by investiga-
tors and IRBs, frequencies of continuing review, and IRB 
comments in IRB review request forms and the minutes of 
each study. Study risk was divided into four levels, as used 
by the IRB of Severance Hospital. The levels of risk included: 
(1) Level 1: no greater than minimal risk; (2) Level 2: minor 
increase over minimal risk; (3) Level 3: moderate risk with 
a medium to high probability of a moderate-severity event; 
and (4) Level 4: high risk greater than a moderate risk study 
due to the increased probability for generating irreversible 
morbidity or serious adverse events. 
IRB comments were classified into eight categories includ-
ing: (1) risk level and data/safety monitoring plan, frequency 
of continuing review, (2) study design, (3) statistics, (4) in-
formed consent form and procedure, (5) research resources 
(research grant, researchers etc.), (6) subject protection, 
(7) minor modification, and (8) more information needed 
based on the classification of Lidz CW et al.16 Since this study 
did not involve human subjects, the study was conducted 
without IRB approval. 
2. Statistical Analysis
Quantitative variables were presented as mean±SD, while 
non-quantitative variables were presented as numerical val-
ues (percentage). Excluding retrospective studies, the results 
of initial review according to diseases, approval duration, 
and comments were analyzed, and variables were compared 
using Student’s t -test, Fisher’s exact test, and the chi-square 
test. The agreement between risk levels decided by inves-
tigators and IRB in IBD and non-IBD studies was assessed 
using a Kappa value, and differences between paired propor-
tions were determined with McNemar’s test. Agreement of 
Kappa values ranging from 0.0 to 1.0 was defined as follows: 
0.00−0.20: slight agreement; 0.2−0.4: fair agreement; 0.4−0.6: 
moderate agreement; 0.6−0.8: substantial agreement; and 
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0.8−1.0: almost perfect agreement. P-values of <0.05 were 
considered statistically significant. All statistical analyses 
were conducted using PASW Statistics 18.0 (ver. 18.0; IBM 
Co., Armonk, NY, USA).
RESULTS
1. Baseline Characteristics of Studies
Of all GI disease research proposals reviewed by the IRB 
of Severance Hospital between January 2009 and December 
2013, 79 were IBD studies and (20.7%) and 302 were non-IBD 
GI studies (79.3%). Of all IBD studies, 27 were IITs (34.2%) 
and 52 were SITs (65.8%). Of all non-IBD GI studies, 104 
were SITs (34.4%) and 198 were SITs (65.6%). No statistically 
significant difference was found between the two groups 
(P=0.965). According to study phase, IBD studies consisted 
of a phase I trial (1.3%), 10 phase II trials (12.7%), 11 phase III 
trials (13.9%), and a phase IV trial (1.3%). Meanwhile, there 
were three post-marketing survey studies (3.8%), 32 clini-
cal trials including registry, cohort, human biospecimen, or 
survey studies (40.5%), and 21 retrospective studies (26.6%). 
There was neither a phase I/II clinical trial nor a clinical trial 
for medical devices. According to the types of study design, a 
statistically significant difference was not detected between 
the two groups (P =0.238). According to initial review data, 
the number of reviewed IBD studies increase annually, and 
then decreased in 2013 compared to 2012. No significant diff-
Table 1. Baseline Characteristics of Clinical Research Between IBD and Non-IBD Gastrointestinal Studies
Characteristics Total (n=381) IBD studies (n=79) Non-IBD studies (n=302) P-value
Study 0.965*
   SIT 131 (34.4) 27 (34.2) 104 (34.4)
   IIT 250 (65.6) 52 (65.8) 198 (65.6)
Phase 0.238†
   Phase I 2 (0.5) 1 (1.3) 1 (0.5)
   Phase I/II 1 (0.3) 0 (0.0) 1 (0.5)
   Phase II 40 (10.5) 10 (12.7) 30 (15.5)
   Phase III 51 (13.4) 11 (13.9) 40 (20.6)
   Phase IV 34 (8.9) 1 (1.3) 33 (17.0)
   Medical device clinical trial 3 (0.8) 0 (0.0) 3 (1.5)
   PMS 17 (4.5) 3 (3.8) 14 (7.2)
   Retrospective study 82 (21.5) 21 (26.6) 61 (31.4)
   Others 151 (39.6) 32 (40.5) 119 (61.3)
No. of study reviewed 0.211†
   2009 56 (14.7) 5 (6.3) 51 (16.9)
   2010 76 (20.0) 15 (19.0) 61 (20.2)
   2011 66 (17.3) 21 (26.6) 45 (14.9)
   2012 99 (26.0) 21 (26.6) 78 (25.8)
   2013 84 (22.0) 17 (21.5) 67 (22.2)
Risk level submitted by investigator 0.000*
   Level 1 273 (76.5) 59 (76.6) 214 (76.4)
   Level 2 66 (18.5) 11 (14.3) 55 (19.6)
   Level 3 12 (3.4) 1 (1.3) 11 (3.9)
   Level 4 6 (1.7) 6 (7.8) 0 (0.0)
Values are presented as n (%).
*Fisher’s exact test.
†Chi-squared test.
SIT, sponsor initiated trial; IIT, investigator initiated trial; PMS, post marketing survey.
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erence was found between the two groups (P=0.211) (Table 1).
2. IRB Review Results
1) Results of Initial Review
This study analyzed 299 prospective trials by categorizing 
them into approved, conditionally approved, approved with 
modification, deferred, or rejected classes. In the compari-
son of results of initial review between the IBD and non-IBD 
GI groups, no significant difference was found between the 
two groups (P =0.368). With respect to the number of IRB 
comments, there were 3.9±4.0 comments in IBD studies and 
3.5±4.1 comments in non-IBD GI studies. Even though the 
number of comments was higher in IBD studies, there was 
no significant difference between the two groups (P=0.580). 
Time from initial review to approval took 28.2±41.8 days in 
IBD studies and 31.6±48.3 days in non-IBD studies. Despite 
the longer duration of approval process in non-IBD GI stud-
ies, no significant difference was observed (P=0.662) (Table 2).
2) Risk Level and Frequency of Continuing Review
Risk levels determined by investigators and IRB were 
compared in 277 of the 299 prospective studies, excluding 
22 studies without risk level. IRB decisions on risk level were 
higher in 15.8% of IBD studies and 27.2% of non-IBD GI stud-
ies. IRB decisions on risk level were significantly higher in 
the non-IBD group (Table 3) (P<0.001). In analysis of agree-
ment between risk levels decided by investigators and IRB, 
both groups showed moderate agreement or higher. The 
degree of agreement was higher in the IBD group than in the 
non-IBD GI group (kappa 0.65 vs. 0.50).17 IRB frequency of 
continuing review was determined by considering the char-
acteristics and risk levels of all reviewed studies. In the IBD 
group, intervals for interim reviews were every 12 months in 
48 studies (82.8%), every 6 months in three studies (5.2%), 
and exempt in seven studies (12.1%). The frequency of con-
tinuing review was determined in all studies during the ini-
tial IRB review. In the non-IBD GI group, intervals for interim 
reviews were every 12 months in 201 studies (83.4%), every 
6 months in 12 studies (5.0%), and exempt in 26 studies 
(10.8%). The frequency of continuing review was not deter-
mined in two studies (0.8%). There was no significant differ-
ence between the two groups (P=0.906).
Table 2. Result of Institutional Review Board (IRB) Review Between IBD and Non-IBD Gastrointestinal Studies 
Results Total (n=299) IBD studies (n=58) Non-IBD studies (n=241) P-value
Result of initial review 0.368*
    Approved 130 (43.5) 30 (51.7) 100 (41.5)
    Approved with modification 122 (40.8) 20 (34.5) 102 (42.3)
    Deferred 47 (15.7) 8 (13.8) 39 (16.2)
    Disapproved 0 (0.0) 0 (0.0) 0 (0.0)
    Tabled 0 (0.0) 0 (0.0) 0 (0.0)
Risk Level 0.001*
    Level 1 147 (49.2) 33 (56.9) 114 (47.3)
    Level 2 101 (33.8) 13 (22.4) 88 (36.5)
    Level 3 44 (14.7) 7 (12.1) 37 (15.4)
    Level 4 7 (2.3) 5 (8.6) 2 (0.8)
Frequency of continuing review 0.906*
    Every 12 mo 249 (83.3) 48 (82.8) 201 (83.4)
    Every 6 mo 15 (5.0) 3 (5.2) 12 (5.0)
    Exempt 33 (11.0) 7 (12.1) 26 (10.8)
    Pending 2 (0.7) 0 (0.0) 2 (0.8)
Number of IRB review comment 3.6±4.2 3.9±4.0 3.5±4.1 0.580†
Duration from submission to approval (days) 30.5±47.0 28.2±41.8 31.6±48.3 0.662†
Values are presented as n (%) or mean±SD.
*Fisher’s exact test.
†Independent t-test.
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3. IRB Review Comments
Comments suggested in the IRB’s initial review were 
analyzed. Table 4 shows the comparison of IRB comments 
between the IBD and non-IBD GI groups. The number of 
comments on risk level, study design, statistics, research 
resources, and minor modification was higher in the non-
IBD GI group. The mean number of comments on “informed 
consent form and procedure” (P <0.001) and “need more 
information” (P =0.01) was significantly higher in the IBD 
group. 
DISCUSSION
To conduct clinical trials in accordance with the principles 
of the Good Clinical Practice (GCP) guidelines, investigators 
are required improve the quality of their studies based on 
overall evaluation and discussion of major IRB comments, 
causes of delayed review, and others from the IRB review 
process after developing a study protocol. This study aimed 
to identify beneficial points to consider when preparing an 
IRB research protocol by comparing types of IRB research, 




Level 1 Level 2 Level 3 Level 4 Total
IBD study 0.050†
   Level 1 33 (57.9) 0 (0.0) 0 (0.0) 0 (0.0) 33 (57.9)
   Level 2 4 (7.0) 8 (14.0) 0 (0.0) 0 (0.0) 12 (21.1)
   Level 3 2 (3.5) 2 (3.5) 1 (1.8) 2 (3.5) 7 (12.3)
   Level 4 0 (0.0) 1 (1.8) 0 (0.0) 4 (7.0) 5 (8.8)
   Total 39 (68.4) 11 (19.3) 1 (1.8) 6 (10.5) 57 
Non-IBD GI study <0.001†
   Level 1 106 (48.2) 0 (0.0) 0 (0.0) 0 (0.0) 106 (48.2)
   Level 2 36 (16.4) 43 (19.6) 2 (1.0) 0 (0.0) 81 (36.8)
   Level 3 11 (5.0) 11 (5.0) 9 (4.1) 0 (0.0) 31 (14.1)
   Level 4 1 (0.4) 1 (0.4) 0 (0.0) 0 (0.0) 2 (0.9)
   Total 154 (70.0) 55 (25.0) 11 (5.0) 0 (0.0) 220 
Values are presented as n (%) or mean±SD. 
Note that percentages of study that risk level elevated are 27.2% for IBD group and 15.8% for non-IBD group, presented as bold section.
*Decision on risk level has been performed since 2010. The number of decision on risk level was 277 since 2010.
†McNemar-Bowker test.
IRB, Institutional Review Board; GI, gastrointestinal.
Table 4. Comparison of IRB Comments Between IBD Research Group and Non-IBD Gastrointestinal Disease Research Group
Variables IBD (n=58) Non-IBD (n=241) P-value*
Risk level/DSMP 0.26±0.44 0.52±0.65 0.680
Study design 0.43±0.94 0.63±1.06 0.420
Statistics 0.09±0.42 0.36±0.61 0.040
Informed consent form and procedure 3.96±3.02 2.30±2.17 <0.001
Research resources 0.13±0.34 0.40±0.58 0.030
Subject protection 0.43±0.79 0.22±0.46 0.080
Minor modification 0.48±0.67 0.67±0.82 0.300
Need more information 0.30±0.56 0.09±0.31 0.010
Values are presented as mean±SD. 
*Independent t-test.
IRB, Institutional Review Board; DSMP, data and safety monitoring plan.
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review results, approval processing times, comments and 
so on between IBD and non-IBD GI studies. SITs accounted 
for 34.2% and 34.4% of all studies in the IBD and non-IBD GI 
groups, respectively, showing no difference between the two 
groups. 
The percentage of SITs was similar in the two groups at ap-
proximately 34%. Since a clinical trial needed for a marketed 
product for every new drug candidate is carried out long-
term, there was no significant increase in absolute num-
ber. The lower proportion of IITs for new drug approval is 
thought to be attributable to time and economic constraints 
resulting from the verification of adaptability and efficacy, 
combined modality, and others. Moreover, the greater per-
centage of IITs for purposes other than new drug approval is 
probably attributable to study materials obtained for clinical 
practice and a wide range of experimental fields. 
Phase III trials account for a large percentage of all clinical 
trial phases. Among all types of study design, “others” includ-
ing registry, cohort, human biospecimen, and survey studies 
accounted for the largest percentage of all categories. There 
was no significant difference in study phase between the two 
groups, because the proportion of other clinical trials is large 
as studies conducted for purposes other than drug develop-
ment are more convenient and various. Since human subject 
research should be performed after gaining IRB approval as 
stated in law after the enforcement of the wholly amended 
Bioethics and Safety Act on February 2, 2013, the number of 
clinical trials classified as “others” is forecasted to grow. 
As the types and number of clinical studies have increased, 
related laws and regulations are being reinforced. Further-
more, the scope of IRB has been expanded as the numbers 
of studies to be reviewed have increased. The numbers of 
studies on GI diseases are also increasing. The percentages 
of IBD and non-IBD GI studies were increased by 40% and 
31.4% from 2009 to 2013, respectively. The increased num-
ber of IBD studies to be reviewed in recent years is thought 
to be attributable to increased prevalence and interest in 
IBD by Korean investigators. 
In terms of levels of risk, the IBD group had more studies 
classified as level 4 (highest risk category) by the investiga-
tors themselves compared to the non-IBD GI group. This 
outcome most likely reflects the nature of chronic inflamma-
tion of the intestines of unknown cause that persistently low-
ers the quality of life in patients and increases the incidence 
of complications such as enterostenosis, fistula, and colon 
cancer.18-20 Taking into account the fact that the age of onset 
is the 10s-20s,21 investigators seem to consider IBD studies 
as high-risk. In the comparison between IRB’s and investiga-
tor’s decisions on risk level, both investigators and IRB had a 
tendency to consider IBD studies as high-risk. The number 
of studies with an elevated level of risk was higher in non-
IBD GI studies compared to IBD studies (27.2% vs. 15.8%). 
Thus, investigators were found to evaluate the risk level of 
their IBD studies more strictly. To make IRB review more 
appropriately without bias, investigators must provide mea-
sures to minimize risk and a data/safety monitoring plan in 
their protocols when applying for IRB review. 
No significant difference was found in the approval rate of 
initial review and duration from submission to first approval 
between the two groups. This is because IRB approval varies 
depending on study protocols and variation is considerable. 
The Standard Operating Procedure (SOP) is to document 
policies and procedures including application, approval, and 
notification for IRB review of research, and the due date for 
submission of answers to reviewers’ comments. This seems 
to be the reason why there was no difference in duration to 
approval between the two groups. However, the IRB process 
takes about a month to review a new protocol, and this re-
mains a problem. We suggest that IRB administrators should 
sufficiently reflect investigator’s answers to IRB review com-
ments as modifications and additional information in the 
pre-review process prior to the second review in order to 
shorten duration to approval. 
There was no difference in IRB frequency of continuing 
review between the two groups. Frequency of continuing 
review is generally determined by considering study design, 
characteristics of subjects, and the risk-benefit ratio. Study 
protocols are typically reviewed on a continual basis at an 
interval of one year, and intervals of continuing review are 
shortened to every 3 or 6 months depending on the degree 
of risk as determined by the IRB. No significant difference 
was detected in the frequency of continuing review between 
the two groups. We consider this outcome as the result of 
the IRB determining the frequency of continuing review as 
12 months in most protocols, and the intervals of continuing 
review have not been shortened in many studies with a risk 
level of 4. 
In the comparison of the number of initial IRB comments 
between IBD and non-IBD GI studies, no significant dif-
ference was found between the two groups. Determining 
significant difference can be difficult for the number of com-
ments, since a single comment in a protocol may point out 
a major error, while several comments in a protocol may 
be minor, requiring minimal modifications. According to 
the types of IRB comments, informed consent forms and 
procedures have been most commonly pointed out in IBD 
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studies, followed by requests for additional information. The 
mean number of other comments was higher in non-IBD GI 
studies, and this needs to be noted since patients with highly 
prevalent diseases are more likely to assess a variety of infor-
mation through general knowledge, mass media, and others 
compared to those with a disease with a low prevalence. 
Patients with relatively less information need to be fully in-
formed with detailed explanations prior to participation in 
the study. Thus, the informed consent form should include 
a detailed and clear explanation of the research when inves-
tigators apply for IRB review. In addition, informed consent 
should be voluntarily obtained and documented by the use 
of a written consent form by performing prior informed con-
sent procedure in accordance with the principles of GCP. 
Ideal reviews could be performed if the IRB Committee 
consists of members with competence in special areas to as-
sist in reviewing key issues. However, it is practically impos-
sible to invite experts in all fields of study as IRB reviewers. 
For this reason, investigators should write their protocols in 
detail when applying for IRB review, in order to minimize 
IRB review opinions on study design and background. Ac-
cording to the results of our analysis, IBD studies had more 
comments requesting additional information compared to 
non-IBD GI studies. Detailed information about diseases 
should be also provided in research documents. Further-
more, the use of pre-review of IRB protocols can shorten ap-
proval processing times and increase approval rates. 
There are several limitations to note in the present study. 
This investigation was a single-center retrospective study 
with a relatively small sample size. Deviation may occur ac-
cording to the specificity of investigators conducting studies 
on IBD. Moreover, deviation may be present depending on 
factors such as IRB reviewers’ experience and preferences 
of the IRB committee. Therefore, the results from this survey 
cannot be generalized. In addition, the effects of external 
factors such as committee members and changes in the IRB 
SOPs have not been considered in the annual analyses. 
In conclusion, IBD studies were not significantly different 
to GI disease studies in terms of duration from submission 
to approval or approval rate. Nevertheless, appropriate deci-
sions on risk level and preparation for protection measures 
are still crucial to the protection of human subjects. Fur-
thermore, IBD investigators can reduce the burdens of the 
IRB approval process by developing research protocols and 
subject information sheets with detailed information and 
descriptions.
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